Piperlonguminine

About: Piperlonguminine is a research topic. Over the lifetime, 106 publications have been published within this topic receiving 3046 citations.

Effect of piperlonguminine on blood lipid metabolism and its related genes expression in hyperlipidemia rats

Abstract: Objective To observe the effects of piperlonguminine on the blood lipid metabolism and its related genes expression in hyperlipidemia rats. Methods The hyperlipidemia models induced by high-fat feeding were established. The piperlonguminine group was fed continuously with piperlonguminine (2.5, 5, and 10 mg/kg) for four weeks. At the last day, all the rats fasted for at least 12 h and the blood was drawn for the measurement of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apolipoproteinA1 (ApoA1), and apolipoprotein B (ApoB); The mRNA expression of low density lipoprotein cholesterol receptor (LDLR), ApoB, and 3-hydroxy 3-methylglutaryl co-enzyme A reductase (HMG-CoAR) were measured by RT-PCR. Results Compared with that of the high-fat model group, the serum TC, TG, LDL-C, ApoB levels, and the ratio of ApoB/ApoA1 were reduced (P0.05) and the serum HDL-C and ApoA1 were increased in the piperlonguminine group (P0.05). Piperlonguminine could increase hepatic LDLR mRNA levels (P0.05) and reduce ApoB mRNA levels (P0.05). But it had no significant effects on HMG-CoAR mRNA level (P0.05). Conclusion Piperlonguminine has the effect of regulating lipid metabolism. The mechanism is likely related to increasing LDLR mRNA expression and decreasing ApoB mRNA expression.

Molecular docking analysis of vascular endothelial growth factor receptor with bioactive molecules from Piper longum as potential anti-cancer agents.

Abstract: It is known that vascular endothelial growth factor receptor (VGFR) is linked with cancer. Therefore, it is of interest to document the molecular binding features of bioactive molecules from Piper longum as potential anti-cancer agents with VGFR2 for further consideration. Thus, we document the binding features of four compounds (sesamin, fargesin, longamide and piperlonguminine) with VGFR2 for further consideration in drug discovery.

Application of piperlongumine alkaloids in preparation of medicines for promoting melanogenesis during treatment of leucoderma

Abstract: The invention relates to application of piperlongumine alkaloids in preparation of medicines for promoting melanogenesis during treatment of leucoderma. The amide alkaloid compounds include isopiperine, piperlonguminine, pseudocapsaicin amide A and pseudocapsaicin amide C, and are subjected to determination of melanogenesis in murine melanoma cells B16 and tyrosinase activity. The results show that, the piperlongumine alkaloids are capable of promoting melanogenesis and tyrosinase activity to different degrees, and can be used for preparing medicines for treating the leucoderma. A favorable material basis is provided for developing medicines for treating leucoderma.

Novel preparation method for preparing piperlonguminine compound having skin whitening activity

Abstract: A method for preparing a piperlonguminine compound is provided to be able to simply mass-produce the piperlonguminine compound having strong whitening activity as an alpha-melanocyte stimulating hormone inhibitor. The method comprises the steps of: (a) after treating an ethyl-4-diethylphosphono-2-butenoate with NaH, performing a modified Wittig condensation on it with a piperonal represented by the formula(2) to obtain an ethyl piperate represented by the formula(4); (b) hydrolyzing the ethyl piperate(4) with a strong base such as KOH so as to obtain a piperinic acid represented by the formula(5); and (c) reacting the piperinic acid(5) with an isobutyl amine in the presence of a boronic acid to obtain a piperlonguminine compound represented by the formula(1a).

Effects of Piperlonguminine on Genes Expression of LOX-1 and VCAM-1 in the Aortic of Atherosclerosis Rabbits

Abstract: OBJECTIVE To observe the effects of piperlonguminine on mRNA expression of lectin-like oxidized low density lipoprotein receptor-1(LOX-1) and vascular cellular adhesion molecule-1(VCAM-1) in atherosclerosis rabbits.METHODS The atherosclerosis model of rabbits was established by feeding high-fat forage.32 New Zealand rabbits were divided randomly and equally into normal group,model group,piperlonguminine group and positive group.The piperlonguminine group and positive group were feed with piperlonguminine and simvastatin at the dose of 5 mg·kg-1·d-1.After 8 weeks,the mRNA expression level of LOX-1 and VCAM-1 were measured by Real-time PCR.RESULTS Compared with that of the normal group,the mRNA expression level of LOX-1 and VCAM-1 were both significantly increased in the model group.The average relative expression ratio of model group were as 16.8 and 8.1 times as that of normal group.Compared with that of the model group,the mRNA expression level of LOX-1 and VCAM-1 were both significantly reduced in the piperlonguminine group.The average relative expression ratio of piperlonguminine group were as 9.8 and 4 times as that of normal groups.Compared with the model group,mRNA expression levels of LOX-1and VCAM-1 were reduced by 42% and 51%.CONCLUSION The inhibition of LOX-1 and VCAM-1 mRNA expression by piperlonguminine in aorta of atherosclerosis rabbits may be its mechanisms for anti-atherosclerotic.